Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride.

Lien LM, Tvedt B, Heinrich D.

Int J Urol Nurs. 2015 Mar;9(1):3-13. Review.

2.

Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.

Delacruz A, Arauz G, Curley T, Lindo A, Jensen T.

Clin J Oncol Nurs. 2015 Apr;19(2):E31-5. doi: 10.1188/15.CJON.E31-E35.

PMID:
25840395
3.

Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.

McGann S, Horton ER.

Ann Pharmacother. 2015 Apr;49(4):469-76. doi: 10.1177/1060028014565444. Review.

PMID:
25573268
4.

Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.

Nilsson S.

Am Soc Clin Oncol Educ Book. 2014:e132-9. doi: 10.14694/EdBook_AM.2014.34.e132. Review.

5.

Radium Ra 223 dichloride in castration-resistant prostate cancer.

Joung JY, Ha YS, Kim IY.

Drugs Today (Barc). 2013 Aug;49(8):483-90. doi: 10.1358/dot.2013.49.8.1968670.

PMID:
23977665
6.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C.

Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4.

PMID:
24836273
7.

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE.

Eur J Cancer. 2017 Jan;71:1-6. doi: 10.1016/j.ejca.2016.10.020.

8.

Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.

Shirley M, McCormack PL.

Drugs. 2014 Apr;74(5):579-86. doi: 10.1007/s40265-014-0198-4. Review.

PMID:
24610703
9.

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D.

Eur Urol. 2016 Nov;70(5):875-883. doi: 10.1016/j.eururo.2016.06.002.

10.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C.

Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7.

PMID:
25439694
11.

The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.

Wilson JM, Parker C.

Expert Rev Anticancer Ther. 2016 Sep;16(9):911-8. doi: 10.1080/14737140.2016.1222273.

PMID:
27501059
12.

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.

Nilsson S.

Expert Opin Drug Saf. 2015 Jul;14(7):1127-36. doi: 10.1517/14740338.2015.1045874.

PMID:
26022669
13.

Radium-223 for the treatment of castration-resistant prostate cancer.

El-Amm J, Aragon-Ching JB.

Onco Targets Ther. 2015 May 18;8:1103-9. doi: 10.2147/OTT.S44291. Review.

14.

Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.

Shore ND.

Urology. 2015 Apr;85(4):717-24. doi: 10.1016/j.urology.2014.11.031. Review.

15.

Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.

Takalkar A, Adams S, Subbiah V.

Exp Hematol Oncol. 2014 Sep 8;3:23. doi: 10.1186/2162-3619-3-23.

16.

Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.

Borsò E, Boni G, Galli L, Ricci S, Farnesi A, Mazzarri S, Cianci C, Mariani G, Falcone A.

Future Oncol. 2015;11(2):323-31. doi: 10.2217/fon.14.157.

PMID:
25075962
17.

Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.

Blacksburg SR, Witten MR, Haas JA.

Curr Treat Options Oncol. 2015 Mar;16(3):325. doi: 10.1007/s11864-014-0325-1. Review.

PMID:
25777571
18.

Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223.

Coleman R.

Semin Nucl Med. 2016 Mar;46(2):99-104. doi: 10.1053/j.semnuclmed.2015.10.012. Review.

PMID:
26897713
19.

Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.

Lewis B, Chalhoub E, Chalouhy C, Sartor O.

Oncology (Williston Park). 2015 Jul;29(7):483-8. Review.

20.

[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].

Tauber R, Gschwend J, Scheidhauer K, Eiber M, Krönke M.

Urologe A. 2017 Jan;56(1):24-31. doi: 10.1007/s00120-016-0300-5. German.

PMID:
28058455
Items per page

Supplemental Content

Support Center